Amphastar Pharmaceuticals Inc. Stock – Fundamental Analysis

Price
26.08
10/14/2026
Jun 2014
Oct 2026

Fundamental Data & Ratios (Balance sheet update: 10/11/2026)

Balance Sheet Total Assets 1,629,299,000.00 ROE 48.41 %
Balance Sheet Total Equity 788,805,000.00 ROA 6.02 %
Cashflow Capital Expenditures -34,882,000.00 P/FCF 10.37
Cashflow Free Cash Flow 121,233,000.00 – –
Cashflow Operating Cash Flow 156,115,000.00 P/CF 8.05
Income Earnings per Share (diluted) 2.03 Div. Yield –
Income Net Income 98,094,000.00 P/E 12.85
Income Shares Outstanding 48,215,000.00 P/B 1.59
Income Total Revenue 719,887,000.00 P/S 1.75

Ratios calculated on: 10/14/2026

Company Description

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.

Advanced Analysis Features

Additional comparison and history views are available after login.

Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.ir.amphastar.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown. Learn more